WO2003024944A1 - An improved process for the preparation of bicyclic antidiabetic compounds - Google Patents

An improved process for the preparation of bicyclic antidiabetic compounds Download PDF

Info

Publication number
WO2003024944A1
WO2003024944A1 PCT/IB2002/003875 IB0203875W WO03024944A1 WO 2003024944 A1 WO2003024944 A1 WO 2003024944A1 IB 0203875 W IB0203875 W IB 0203875W WO 03024944 A1 WO03024944 A1 WO 03024944A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
toluene
preparation
temperature
Prior art date
Application number
PCT/IB2002/003875
Other languages
French (fr)
Inventor
Chandrasekhar Batchu
Sivarama Prasad Addanki
Ramabhadra Sarma Mamillapalli
Om Reddy Gaddam
Original Assignee
Dr. Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2003024944A1 publication Critical patent/WO2003024944A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/161,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The present invention relates to an improved process for the preparation of antidiabetic compounds having the formula (1), where R1 represents (C¿1?-C6)alkyl group, X represents sulphur or oxygen atom.

Description

AN IMPROVED PROCESS FOR THE PREPARATION, OF BiςYCLIC ANTIDIABETIC COMPOUNDS
Field of the invention
The present invention relates to an improved process for the preparation of antidiabetic compounds having the formula (1).
Figure imgf000002_0001
where R represents (Cι-Ce)alkyl group, X represents sulphur or oxygen atom.
In our US Patent number 6,265,401 we have described a process for the preparation of compounds of formula (1). The process described therein comprises of converting aldehyde of formula (2) to a compound of formula (3) where' all symbols' are as defined above and R represents lower alkyl group, reducing the compound of formula (3) to produce a compound of formula (4), hydrolysing the compound of formula (4) to obtain an acid of formula (5), converting the acid of formula (5) to an amide of the formula (6) and hydrolysing the amide to produce the compound of formula (1), where X and R1 are as defined above. The process is shown in the scheme -1 given below:
Figure imgf000002_0002
(1)
Scheme-1
By recognizing the importance of the antidiabetic compound, we continued our research efforts to develop a more efficient, simple and commercially viable stereoselective process for the preparation of the said novel compounds of the formula (1).
While developing the improved process we observed that the process for the preparation of the compounds of the formula (1) as disclosed in our above-referred, patent involves
> the use of reactions like Wittig-Horner, which is a moisture sensitive reaction, to prepare the compound of the formula (3). Moisture sensitive reactions are difficult to handle in large scale manufacturing process.
> tedious reaction steps employing expensive and time consuming column chromatographic methods the overall yield of the compounds of the formula (1) is only -2.5% and time cycle required for the completion of the reaction sequence resulting in the compounds of the formula (1) is very long which makes the process very expensive for commercial application . In our WO publication No. 00/66572 we have described^an alternate process for the preparation of compounds of formula (1). The process described therein comprises' the condensation of compound of the formula (7), with mesylate of the formula (8) in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof and base such as K2CO3, Na2CO3; NaH and the like to produce ester of formula (9) and hydrolysing the compound of the formula (9) by conventional methods to yield the compound of the general formula (1). The reaction is shown in scheme-2 below:
Figure imgf000003_0001
(1)
Scheme-2 The above process has the following disadvantages:
> the condensation of mesylate with compound of formula (7) in DMF and potassium carbonate results into highly impure product, which could not be purified by conventional methods like distillation column chrortiatography was employed for the isolatiorl' and purification of1 the product, which is difficult to practice in scale up trials.
> DMF is used as medium, the recovery and recycling of DMF in bulk quantities poses a problem as it absorbs moisture and decomposes during distillation.
Objectives of the present invention
The main objective of the present invention is therefore to provide an improved process for the preparation of the compounds of the formula (1), thereby making the process commercially viable. Yet another objective of the present invention is to provide a simple and efficient process for1 the preparation of the compounds of the^formula (1), which' would be easy to handle for a manufacturing chemist with simple and safe operations even in scale up of the process for commercial applications.
Detailed description of the invention
Accordingly, the present invention provides an improved process for the preparation of compounds of the formula (1)
Figure imgf000004_0001
where R1 represents, ( -Cό^lkyl group such as methyl, ethyl, propyl, isopropyl,, butyl, isobutyl, t-butyl and the like; X represents sulphur or oxygen atom, which comprises'
(i) condensing the compound of the formula (7) where R1 and R2 represent (Ci- C6)alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl, with mesylate of the formula (8) where X represents sulphur or oxygen atom in the presence of a base and a solvent at a temperature and duration in the range of 20 to
150 °C and 1.5 to 30 h respectively, to give the ester of the formula (9) where R1 represents (Cι-C6)alkyl group, R represents propyl, isopropyl, butyl, isobutyl or t- butyl, X represents sulphur or oxygen atom,
(ii) hydrolysing the compound of the formula (9) by conventional methods to yield the compound of the formula (1) defined above, by using a solverit and a base' at a temperature and duration in the range of 10 to 40 °C and 20 min to 12 h respectively and
(iii) isolating the compound of formula (I) by conventional methods.
The process explained above is shown in scheme-3 below:
Figure imgf000005_0001
(1)
Scheme-3
The condensation of compound of formula (7) with mesylate of compound of formula (8) may be carried in the presence of base such as sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide and the like, using solvents such as toluene, xylene and the like or mixtures thereof or alcohols such as methanol, ethanol, propanol, isopropanol and the like or mixtures thereof.
The hydrolysis of compound of formula (9) may be carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate and the like using solvent such as toluene, xylene and the like or mixtures thereof or alcohols such as methanol,1' ethanol, propanol,' isopropanol and the like or mixtures thereof. The reaction may be carried out at a temperature in the range of preferably at 25 to 35 °C. The reaction time preferably may range from 20 min to 8 h. The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention. Example 1 Step (i)
Preparation of (-)ethyl-3-[4-[2-(3,4-dihydro-2H-benzo b]ri ,41thiazin-4-yl) ethoxylphenyll-2-ethoxypropanoate
In a 1 L four necked round bottom flask, fitted with a Dean-Stark apparatus, reflux condenser and efficient stirrer, powdered K2C03 (55 g) and toluene (540 ml) were added at 25-35 °C under stirring. The reaction mixture was heated to 110-120 °C and maintained reflux temperature of toluene for 2-3 h. Water was removed azeotropically till no more water droplets were observed. After azeotropic removal of water, the reaction mixture was cooled to 75-85 °C and added 2-(3,4-dihydro-2H- benzo[b][l,4]thiazin-4-yl)ethylmethane sulphonate (27.8 g), (-)ethyl 2-ethoxy-3-(4- hydroxyphenyl)propanoate (23.8 g) sequentially in one lot. The reaction mixture was heated to 110-120 °C and maintained the gentle reflux of toluene. Then water was removed azeotropically and maintained the reaction mixture under reflux for 4-5 h. The reaction mixture was brought to room temperature and cooled tol0-15 °C and water (200 ml) was added and separated the toluene layer. The toluene layer was washed with DM water till pH becomes neutral. The toluene layer was washed with 10 %" HC1 and DM water till pH becomes neutral. The toluene layer was concentrated at temperature <100 °C under vacuum till no more drops of toluene were observed. High vacuum was applied at that temperature for 20-30 min to afford pure (-) ethyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][l,4]thiazin-4-yl)ethoxy]phenyl]-2- ethoxy propanoate as light to dark brown clear liquid (weighs about 88 g, yield 92 %, purity 97 %).
IR (neat) cm"1: 3060 (-C-H aromatic stretch), 2922 (-C-H aliphatic stretch), 1740 (- COOEt stretch).
1H NMR (200 MHz, CDC13): δl.1-1.30 (m, 6H), 2.94 (d, J=6.42Hz, 2H), 3.01-3.10 (m, 2H), 3-.28-3.68 (m, 2H), 3.70-3.80 (m, 4H), 3.95 (t, J=6.42Hz, IH), 4.10-4.22 (m, 2H), 6.55-6.74 (m, 2H), 6.80 (d, J=8.63Hz, 2H), 6.98-7.10 (m, 2H), 7.14 (d, J=8.63Hz, 2H). Mass m/z (CI): 416 (M+ + l). Step (ii) Preparation of (-)-3-r4-[2-(3,4-dihydro-2H-benzorbiri,41thiazin-4-yl)ethoxyl phenyll-2-ethoxypropanoic acid
In a 1 L four necked round bottom flask, fitted with a plain aerial condenser and mechanical stirrer (-)ethyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][l,4]thiazin-4-yl) ethoxy}phenyl]-2-ethoxypropanoate (33 g) and methanol (153 ml) were added at 25- 35 °C under stirring. The reaction mixture was cooled to 10-15 °C and 10 % NaOH solution (170 ml) was added slowly maintaining the temperature below 20 °C in about 20-30 min. After complete addition, the reaction mixture was brought to 25-35 °C and maintained under stirring for completion of the reaction. After completion of the reaction, water (75 ml) was added to the reaction mixture and washed with toluene. The aqueous layer was acidified with 25 % sulphuric acid (101 ml) at 15-20 °C to pH 2.5-3.0. The aqueous layer was extracted with toluene. The combined toluene extracts were washed with DM water and concentrated below 100 °C using 100-150 mm vacuum till no more drops of toluene were observed. High vacuum wasi applied below <100 °C for removal of traces of toluene to afford pure (-)-3-[4-[2- (3,4-dihydro-2H-benzo[b][l,4]thiazin-4-yl)ethoxy]phenyl]-2-ethoxy propanoic acid as dark brown, glassy, sticky mass (weighs about 25 g, yield 82 %, purity 97 % by HPLC.
IR (neat) cm"1 : 3400-3300 (-OH stretch), 3060 (-C-H aromatic stretch), 2922 (-C-H aliphatic stretch), 1720 (-COOH stretch). 1H NMR (200 MHz, CDC13): δ 1.18 (t, J=7.0Hz, 3H), 2.82-3.15 (complex, 4H), 3.40- 3.68 (complex, 4H), 3.7-3.81 (complex, 4H), 4.05 (dd, J=7.29 and 4.33Hz, IH), 4.16 (t, J=5.72Hz, 2H), 6.68-6.74 (complex, 2H), 6.81 (d, J=8.5Hz, 2H), 6.94-7.06 (complex, 2H), 7.14 (d, J=8.5Hz, 2H), COOH proton is too broad to observe. Mass m/z (CI): 388 (M+ + 1). Example 2
Step (i)
Preparation of (-)isopropyl 3-r4-r2-(3,4-dihydro-2H-benzorbiri,41thiazm-4-yl) ethoxylphenyll-2-ethoxypropanoate In a 5L four necked round bottom flask, fitted with a dean stark apparatus, reflux condenser and efficient stirrer, powdered K2C03 (565 g) and toluene (3 L) were added at 25-35 °C under stirring. The reaction mixture was heated to 110-120 °C and maintained reflux of toluene for 2-3 h. Water was removed azeotropically till no more water droplets were observed. After azeotropic removal of water, the reaction mixture was cooled to 75-85 °C and added 2-(3, 4-dihydro-2H-benzo[ό][l,4]thiazin- 4-yl)ethylmethane sulphonate (250 g), (-)isopropyl 2-ethoxy-3-(4- hydroxyphenyl)propanoate (207 g) sequentially in one lot. The reaction mixture was heated to 110-120 °C and maintained the gentle reflux of toluene. The water was removed azeotropically maintained the reaction mixture under reflux for 4-5 h. The reaction mixture was brought to room temperature and cooled tol0-15 °C, water (1.5 L) was added and separated the toluene layer. The toluene layer was washed with DM water till pH becomes neutral. The toluene layer was washed with 10 % HC1 and washed with DM water till pH becomes neutral. The toluene layer was
' I' ι _ , > concentrated at temperature <100 °C under vacuum till no more drops of toluene were observed. High vacuum was applied at that temperature for 20-30 min to afford pure (-)isopropyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][l,4]thiazm-4-yl)ethoxy]phenyl]- 2-ethoxypropanoate as light to dark brown clear liquid (weighs 354 g, yield 93 %, purity 97 %).
IR (neat) cm"1 : 3060 (-C-H aromatic stretch), 2922 (-C-H aliphatic stretch), 1740 (- COOCH(CH3)2 stretch).
1H NMR (200 MHz, CDC13): δ 1.1-1.30 (m, 12H), 2.94 (d, J=6.42Hz, 2H), 3.01-3.10 (m, 2H), 3.28-3.68 (m, 2H), 3.70-3.80 (m, 4H), 3.95 (t, J=6.42Hz, IH), 4.10-4.22 (m, 2H), 6.55-6.74 (m, 2H), 6.80 (d, J=8.63Hz, 2H), 6.98-7.10 (m, 2H), 7.14 (d, J=8.63Hz, 2H). Mass m/z (CI): 430 (M+ + l). Step (ii)
Preparation of (-)-3-r4-r2-(3,4-dihydro-2H-benzo[bl [1 ,41thiazin-4-yl) ethoxylphenyl] -2-ethoxypropanoic acid
In a 10 L four necked round bottom flask, fitted with a plain aerial condenser and mechanical stirrer (-)isopropyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][l,4]thiazin-4-yl) ethoxy]phenyl]-2-ethoxypropanoate (330 g) and methanol (2.4 L) were added at 25- 35 °C under stirring. The reaction mixture was cooled to 10-15 °C and 20 % NaOH solution (800 ml) was added slowly maintaining the temperature below 20 °C in about 20-30 min. After complete addition, the reaction mixture was brought to 25-35 °C and maintained under stirring. After completion of the reaction, water (750 ml) was added and washed with toluene. The aqueous layer was acidified with 15-16 % hydrochloric acid (1.3 L) at 15-20 °C and extracted with toluene. The combined toluene extracts were washed with DM water and concentrated the toluene layer below 100 °C using 100-150 mm vacuum till no more drops of toluene were observed. High vacuum was applied below <100 °C for removal of traces of toluene to afford (-)-3-[4-[2-(3,4-dihydro-2H-benzo[b] [1 ,4]thiazin-4-yl)ethoxy]phenyl]-2- ethoxypropanoic acid as light brown, glass, sticky mass (weighs about 251 g, yield 85 %, purity 97 % by HPLC). IR (neat) cm"1 : 3400,-3300 (-OH stretch), 3060 (-C-H aromatic stretch), ( 2922 (-C-H, aliphatic stretch), 1720 (-COOH stretch).
TI NMR (200 MHz, CDC13): δ 1.18 (t, J=7.0Hz, 3H), 2.82-3.15 (complex, 4H), 3.40- 3.68 (complex, 4H), 3.7-3.81 (complex, 4H), 4.05 (dd, J=7.29 and 4.33Hz, IH), 4.16 (t, J=5.72Hz, 2H), 6.68-6.74 (complex, 2H), 6.81 (d, J=8.5Hz, 2H), 6.94-7.06 (complex, 2H), 7.14 (d, J=8.5Hz, 2H), COOH proton is too broad to observe. Mass m/z (CI): 388 (M* + 1).
Advantages of the present invention
• The compound of the formula (1) has been developed without employing expensive chemicals, which is commercially viable, simple and efficient with safe operations eyen in scale-up reactions. The use of column chromatography has been avoided completely thereby, making, the process cost and time effective.
The use of new solvent has improved the overall yield of the compound of fonnula (I) and the time cycle required for the production of the compound of the formula (1) has been reduced drastically, which makes the process commercially viable.

Claims

We claim:
1. A process for the preparation of compounds of the formula ( 1 )
Figure imgf000011_0001
where R represents (Cι-C6)alkyl group; X represents sulphur or oxygen atom, which comprises:
(i) condensing th,e compound of the formula (7)
Figure imgf000011_0002
where R1 and R2 represent (C1-C6)alkyl group, with mesylate of the formula (8)
Figure imgf000011_0003
where X represents sulphur or oxygen atom in the presence of a base and a solvent at a temperature and duration in the range of 10 to 150 °C and 2 to 30 h respectively, to give the ester of the formula (9)
Figure imgf000011_0004
where R , 1 , R r>2 and X are as defined above, (ii) hydrolysing the compound of the formula (9) by conventional methods to yield the compound of the formula (1) defined above, by using a base and a solvent at a temperature and duration in the range of 10 to 40 °C and 20 min to 12 h respectively and (iii) isolating the compound of formula (1) by conventional methods.
2. The process as claimed in claim 1, where the base used in step (i) is selected from "sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
3. The process as claimed in claims 1 and 2, where the solvents used in step (i) is selected from toluene, xylene or alcohol selected from methanol, ethanol, propanol, isopropanol or mixtures thereof.
4. The process as claimed in claims 1 to 3, where the base used in step (ii) is selected from sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
5. The process as claimed in claims 1 to 4, where the solvent used in step (ii) is selected fr.om toluene, xylene or alcohol selected from methanol, ethanol, propanol, isopropanol or mixtures thereof.
6. The process as claimed in claims 1 to 5, where the hydrolysis in step (ii) carried out at a temperature in the range of 25 to 35 °C and duration in the range of 20 min to 8 h.
7. A process for the preparation of compound of the formula (1) as claimed in claims 1-6, substantially as herein described with reference to example 1.
PCT/IB2002/003875 2001-09-20 2002-09-20 An improved process for the preparation of bicyclic antidiabetic compounds WO2003024944A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN778MU2001 2001-09-20
IN778/MAS/2001 2001-09-20

Publications (1)

Publication Number Publication Date
WO2003024944A1 true WO2003024944A1 (en) 2003-03-27

Family

ID=11097281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003875 WO2003024944A1 (en) 2001-09-20 2002-09-20 An improved process for the preparation of bicyclic antidiabetic compounds

Country Status (1)

Country Link
WO (1) WO2003024944A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099800A1 (en) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited An improved process for the preparation of bicyclic antidiabetic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066572A1 (en) * 1999-04-28 2000-11-09 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066572A1 (en) * 1999-04-28 2000-11-09 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099800A1 (en) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited An improved process for the preparation of bicyclic antidiabetic agents

Similar Documents

Publication Publication Date Title
US8394961B2 (en) Method for the preparation of dabigatran
US20100249411A1 (en) Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines
CA2002671C (en) Process for the production of 4,5-dichloro-6-ethyl-pyrimidine
WO2003024944A1 (en) An improved process for the preparation of bicyclic antidiabetic compounds
CA2412543C (en) Process for the preparation of quinoline derivatives
HU227319B1 (en) Process for the production of (2-chloro-ethoxy)-acetic acid-n,n-dimethylamide and its intermediate and the novel intermediate
US5304650A (en) Process for the preparation of alkyl N-(hydroxyalkyl)-carbamates
JPH0770037A (en) Production of cyanoacylcyclopropane compound and 2-cyanoacyl-4-butanolide compound used therefor
US20060089509A1 (en) Preparation of substituted alkanesulfonates from 2-hydroxyalkanesulfonates
EP1367052B1 (en) Intermediate for the preparation of carvedilol
AU2006310551B2 (en) Process for the preparation of pyridylcarboxylic amides and esters
WO2006115171A1 (en) Method for producing nicotinic acid derivative or salt thereof
JP4191008B2 (en) Method for producing aminocarboxylic acid ester
WO2003099800A1 (en) An improved process for the preparation of bicyclic antidiabetic agents
EP0402561B1 (en) Process for the manufacture of anilinofumarate via chloromaleate or chlorofumarate or mixtures thereof
KR102570646B1 (en) Method for synthesizing trans-4-[4-(3-methoxy-4-nitrophenyl)-1-piperazinyl]adamantan-1-ol
KR20020056943A (en) Process for the production of trifluoromethylacetophenones
JP4361290B2 (en) Esculetin derivative, method for producing the same, and method for purifying esculetin
KR20080097708A (en) Process for preparation of sarpogrelate hcl salt
EP0298543B1 (en) Thiapentanamide derivatives
CA2041838C (en) Process for preparing benzyl methacrylate and its halogenated or alkyl derivatives on the aromatic ring
WO2023156905A1 (en) A process for the preparation of triclopyr-butotyl
JP4569187B2 (en) Process for producing 4-cyanotetrahydropyran
CA2251637C (en) Novel substituted [2-(1-piperazinyl)ethoxy]methyl
JP4039026B2 (en) Method for producing 3-amino-2-thiophenecarboxylic acid ester

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP